May 12, 2020
Obesity Market Review 2016-2019 and Outlook 2020-2024
Mar 31, 2020
Saxenda® Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity
Feb 13, 2020
FDA In Brief: FDA Requests Voluntary Withdrawal of Weight-Loss Medication After Clinical Trial Shows an Increased Occurrence of Cancer
Jan 15, 2020
Hanmi Pharmaceutical participated in the 38th J.P. Morgan Healthcare Conference, announces that it is "ready to lead global pharmaceutical market with innovative R&D pipeline"
Oct 30, 2019
Research Forum to Highlight Novel Anti-obesity Medications Media Availability on Nov. 4, 2019, at 12:30 p.m. (PST)
Aug 15, 2019
First-of-Its-Kind Research Demonstrates Significant Increase in Weight Loss When Medication Is Precisely Incorporated into Management Programs
Jun 18, 2019
Global Anti-Obesity Drugs Market Outlook to 2024: Online Drug Stores Boost Sales
Jun 18, 2019
Anti-Obesity Prescription Drugs Market to Cross US$ 1,000 Million by 2026, Says TMR
Feb 25, 2019
FDA Accepts Eisai's Supplemental New Drug Application (sNDA) to Update the Labeling for Anti-Obesity Agent BELVIQ® (lorcaserin HCl)
Dec 07, 2018
Anti-obesity Drugs: Global Markets, 2022
Dec 05, 2018
Visiongain Report Looks at Opportunities Within the $6.3bn Anti-Obesity Drugs Market
Aug 27, 2018
Eisai Announces Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ® Presented at the European Society of Cardiology and Published in the New England Journal of Medicine
Jul 17, 2018
Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI 61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®
Feb 01, 2018
Global Anti-Obesity Drugs Market 2017-2023: Market is Estimated to Witness a CAGR of 20.9% - Key Players are F. Hoffmann La Roche, GSK, Orexigen Therapeutics, Vivus Therapeutics, and Eisai
Nov 21, 2017
Anti-Obesity Prescription Drugs Market to Represent a Value of Over US$ 1,000 Million by the End of 2026: Transparency Market Research